First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-12-18 16:47:13 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.jtho.2025.10.016
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1556086425028904
其他信息:
出版社: Elsevier BV
作者: Martin Reck; Jyoti D. Patel; Jhanelle E. Gray; Noemí Reguart; Manuel Cobo; José Fuentes Pradera; Enriqueta Felip; Federico Cappuzzo; Edward B. Garon; Joel W. Neal; Sabeen Mekan; Farnoush Safavi; Nelumka Fernando; Marianna Zavodovskaya; Juliane M. Jürgensmeier; Michael Chisamore; Byoung Chul Cho
